“I expressed deep concerns with your nomination, Secretary Kennedy, and somehow, unfortunately, you have exceeded my expectations in the worst possible ways,” U.S. Rep. Frank Pallone, D-N.J., told Health and Human Services (HHS) Secretary Robert Kennedy during a June 24 House subcommittee hearing.
Atopic dermatitis data from Nektar Therapeutics Inc. put investors even more in the mood for further results with rezpegaldesleukin (rezpeg), an IL-2 pathway agonist and regulatory T-cell proliferator, also in the works for severe to very severe alopecia areata.
Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to build its own global commercial infrastructure, instead of partnering outside the U.S. as it had originally intended. “We’ve concluded that the best way for us to achieve our goals with our rich pipeline is to direct our own global development and commercial strategies and to operationalize these both inside and outside the U.S. through our own organization,” Mark Goldsmith, president and CEO of Revolution Medicines (Revmed), told investors June 24.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bayer, Bio-Thera, Cel-Sci, Cycle, Eisai, Eli Lilly, Excellthera, Exelixis, Gilead, GSK, Incyte, Ipsen, Johnson & Johnson, Madrigal, Merck, Orion, Regeneron, Relief, Sanofi, Springworks.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abtherx, GPCR, Indivior, Neurocrine, Prothena.
RSS
